EA201791875A1 - Комбинированная композиция тезофензина и бета-блокатора - Google Patents

Комбинированная композиция тезофензина и бета-блокатора

Info

Publication number
EA201791875A1
EA201791875A1 EA201791875A EA201791875A EA201791875A1 EA 201791875 A1 EA201791875 A1 EA 201791875A1 EA 201791875 A EA201791875 A EA 201791875A EA 201791875 A EA201791875 A EA 201791875A EA 201791875 A1 EA201791875 A1 EA 201791875A1
Authority
EA
Eurasian Patent Office
Prior art keywords
beta blocker
thesophenzine
combined composition
composition
obesity
Prior art date
Application number
EA201791875A
Other languages
English (en)
Other versions
EA033298B1 (ru
Inventor
Петер Г. Нильсен
Микаэл С. Томсен
Бент Хойгорд
Original Assignee
Саниона А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саниона А/С filed Critical Саниона А/С
Publication of EA201791875A1 publication Critical patent/EA201791875A1/ru
Publication of EA033298B1 publication Critical patent/EA033298B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к композиции с контролируемым высвобождением, содержащей активные соединения тезофензина и бета-блокатор, такой как метопролол или карведилол или их фармацевтически приемлемая соль. Данное изобретение также относится к применению композиции с контролируемым высвобождением в способе лечения диабета, ожирения или нарушения, связанного с ожирением.
EA201791875A 2015-03-03 2016-03-02 Комбинированная лекарственная форма тезофензина и метопролола EA033298B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570117 2015-03-03
DKPA201570644 2015-10-09
PCT/DK2016/050058 WO2016138908A1 (en) 2015-03-03 2016-03-02 Tesofensine, beta blocker combination formulation

Publications (2)

Publication Number Publication Date
EA201791875A1 true EA201791875A1 (ru) 2017-12-29
EA033298B1 EA033298B1 (ru) 2019-09-30

Family

ID=55589632

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791875A EA033298B1 (ru) 2015-03-03 2016-03-02 Комбинированная лекарственная форма тезофензина и метопролола

Country Status (33)

Country Link
US (6) US10231951B2 (ru)
EP (1) EP3265126B1 (ru)
JP (1) JP6772430B2 (ru)
KR (1) KR101999463B1 (ru)
CN (1) CN107666913B (ru)
AU (1) AU2016228002B2 (ru)
CA (1) CA2977415A1 (ru)
CL (1) CL2017002214A1 (ru)
CO (1) CO2017009930A2 (ru)
CR (1) CR20170447A (ru)
DK (1) DK3265126T3 (ru)
DO (1) DOP2017000219A (ru)
EA (1) EA033298B1 (ru)
EC (1) ECSP17059323A (ru)
ES (1) ES2885437T3 (ru)
GT (1) GT201700194A (ru)
HK (1) HK1247127A1 (ru)
HR (1) HRP20211361T1 (ru)
HU (1) HUE055974T2 (ru)
IL (1) IL254179B (ru)
LT (1) LT3265126T (ru)
MA (1) MA41634B1 (ru)
MX (1) MX2017011257A (ru)
PE (1) PE20180187A1 (ru)
PH (1) PH12017501509B1 (ru)
PL (1) PL3265126T3 (ru)
PT (1) PT3265126T (ru)
RS (1) RS62275B1 (ru)
SA (1) SA517382209B1 (ru)
SG (1) SG11201706899VA (ru)
SI (1) SI3265126T1 (ru)
UA (1) UA122224C2 (ru)
WO (1) WO2016138908A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704987T3 (es) * 2012-02-16 2019-03-21 Saniona As Composiciones farmacéuticas para terapia de combinación
US20190060301A1 (en) * 2016-01-15 2019-02-28 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
BR112021013463A2 (pt) * 2019-01-07 2021-09-14 Saniona A/S Tesofensina para redução do peso corporal em pacientes com prader-willi
JP2023523738A (ja) 2020-04-22 2023-06-07 サニオナ エー／エス 視床下部性肥満症の処置
CN117045610B (zh) * 2023-08-24 2024-04-30 杭州沐源生物医药科技有限公司 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0677291A3 (en) 1991-03-18 1996-08-07 Sepracor Inc Composition and method containing optically pure S-metoprolol.
AU720358B2 (en) 1996-02-22 2000-06-01 Neurosearch A/S Tropane-derivatives, their preparation and use
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO2004069234A1 (en) 2003-02-05 2004-08-19 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
WO2004096810A1 (en) 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
CA2553649A1 (en) 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
PL1842534T3 (pl) 2006-02-24 2012-05-31 Teva Pharma Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
US20090068260A1 (en) * 2006-02-24 2009-03-12 Tomer Gold Beta-1-selective adrenoceptor blocking agent compositions and methods for their preparation
US8815285B2 (en) 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
DE102006020604A1 (de) 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
BRPI0714586A2 (pt) 2006-07-28 2013-05-07 Farmaprojects S A formulaÇço farmacÊutica de liberaÇço prolongada de metropolol e processo para a sua preparaÇço
WO2009065845A1 (en) 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
WO2009080691A2 (en) 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
WO2009080693A2 (en) 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
AU2008342250A1 (en) 2007-12-27 2009-07-09 Bayer Animal Health Gmbh Treatment of heart disease using beta-blockers
PT2406253E (pt) 2009-03-11 2013-09-11 Pfizer Derivados de benzofuranilo utilizados como inibidores de glucocinase
SG175995A1 (en) 2009-06-05 2011-12-29 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
CN102145000A (zh) * 2010-02-06 2011-08-10 赤峰维康生化制药有限公司 一种坎地沙坦酯和美托洛尔复方制剂
WO2011100659A2 (en) 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
CN102198112A (zh) * 2010-03-26 2011-09-28 北京天衡药物研究院 一种渗透泵型控释片及其制备方法
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
WO2011144975A1 (en) * 2010-05-15 2011-11-24 Jubilant Life Sciences Limited Multi-unit compositions
WO2012052834A2 (en) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Multiple unit particulate system comprising metoprolol succinate
EP2704697B1 (en) 2011-05-06 2018-09-12 GlaxoSmithKline Consumer Healthcare (UK) IP Limited Sustained release paracetamol formulations
EP2726062A1 (en) * 2011-06-29 2014-05-07 Ranbaxy Laboratories Limited Multilayered dosage form
EP2747757A1 (en) 2011-08-26 2014-07-02 Wockhardt Limited Methods for treating cardiovascular disorders
JP5911969B2 (ja) 2011-12-09 2016-04-27 ウォックハート リミテッド 心臓血管障害の治療方法
ES2704987T3 (es) * 2012-02-16 2019-03-21 Saniona As Composiciones farmacéuticas para terapia de combinación
IN2012DE00826A (ru) 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN102626396B (zh) * 2012-04-28 2014-05-07 海南华益泰康药业有限公司 一种美托洛尔缓释片剂及其制备方法
US20160143864A1 (en) 2013-07-09 2016-05-26 Sun Pharmaceutical Industries Limited Extended-release pharmaceutical compositions of metoprolol

Also Published As

Publication number Publication date
US10828278B2 (en) 2020-11-10
PE20180187A1 (es) 2018-01-23
GT201700194A (es) 2019-06-12
AU2016228002B2 (en) 2020-10-01
PL3265126T3 (pl) 2021-12-06
IL254179B (en) 2020-11-30
US20160279067A1 (en) 2016-09-29
ECSP17059323A (es) 2018-06-30
CO2017009930A2 (es) 2018-01-05
MA41634B1 (fr) 2021-09-30
MX2017011257A (es) 2018-04-10
SI3265126T1 (sl) 2021-11-30
HK1247127A1 (zh) 2018-09-21
LT3265126T (lt) 2021-09-10
JP6772430B2 (ja) 2020-10-21
US10231951B2 (en) 2019-03-19
AU2016228002A1 (en) 2017-09-14
US20180360804A1 (en) 2018-12-20
JP2018507875A (ja) 2018-03-22
US20200129478A1 (en) 2020-04-30
PT3265126T (pt) 2021-08-30
KR20170134393A (ko) 2017-12-06
EP3265126A1 (en) 2018-01-10
SA517382209B1 (ar) 2021-04-19
HRP20211361T1 (hr) 2021-11-26
CR20170447A (es) 2018-03-13
DOP2017000219A (es) 2018-02-15
UA122224C2 (uk) 2020-10-12
RS62275B1 (sr) 2021-09-30
CA2977415A1 (en) 2016-09-09
SG11201706899VA (en) 2017-09-28
IL254179A0 (en) 2017-10-31
EP3265126B1 (en) 2021-06-02
MA41634A (fr) 2018-01-09
US10537551B2 (en) 2020-01-21
PH12017501509A1 (en) 2018-02-05
CL2017002214A1 (es) 2018-04-13
US20210023050A1 (en) 2021-01-28
PH12017501509B1 (en) 2018-02-05
CN107666913A (zh) 2018-02-06
US20180071250A1 (en) 2018-03-15
BR112017018871A2 (pt) 2018-04-17
WO2016138908A1 (en) 2016-09-09
ES2885437T3 (es) 2021-12-13
US11426383B2 (en) 2022-08-30
HUE055974T2 (hu) 2022-01-28
CN107666913B (zh) 2021-11-26
US20230092397A1 (en) 2023-03-23
EA033298B1 (ru) 2019-09-30
US9579288B2 (en) 2017-02-28
DK3265126T3 (da) 2021-09-13
KR101999463B1 (ko) 2019-10-01

Similar Documents

Publication Publication Date Title
EA201791875A1 (ru) Комбинированная композиция тезофензина и бета-блокатора
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
GB2541571A (en) Pharmaceutical compositions
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2016016534A (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
PT3574912T (pt) Composição para tratamento de doença diabética
TR201604127A2 (en) Use of composition that contains local anesthetic for treating nausea
AR103830A1 (es) Formulación de combinación de tesofensina y betabloqueante
MX2017000087A (es) Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.
PH12016502466A1 (en) Ppar compounds for use in the treatment of fibrotic diseases